Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Europe. The aim of this trial is, to investigate the effect of upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in subjects with type 2 diabetes.
Interventions
DRUGsemaglutide
All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
Sponsors
Novo Nordisk A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, aged 18-80 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 18.5-39.9 kg/m\^2 (both inclusive) * Subjects diagnosed clinically with type 2 diabetes mellitus for at least 180 days prior to the first screening visit * For subjects with upper gastrointestinal (GI) disease: Diagnosed with chronic gastritis and/or gastroesophageal reflux disease (GERD) at screening
Exclusion criteria
* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method (adequate contraceptive measures as required by local regulation or practice). (Highly effective contraceptive methods are considered those with a failure rate less than 1% undesired pregnancies per year including surgical sterilisation, hormonal intrauterine devices (coil), oral hormonal contraceptives, sexual abstinence or a surgically sterilised partner) * History of pancreatitis (acute or chronic) * History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) * Unable or unwilling to refrain from smoking during the in-patient periods * Any blood draw in excess of 50 mL in the past 30 days, or donation of blood or plasma in excess of 400 mL within 90 days of the first screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the semaglutide plasma concentration-time curve | From 0 to 24 hours after the 10th dosing |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed semaglutide plasma concentration | From 0 to 24 hours after the 10th dosing |
| Area under the SNAC plasma concentration-time curve | During a dosing interval (0 to 24 hours) at steady state |
| Maximum observed SNAC plasma concentration | During a dosing interval (0 to 24 hours) at steady state |
Countries
Germany
Outcome results
None listed